Comparative Pharmacology
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus FLOMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus FLOMAX.
ALFUZOSIN HYDROCHLORIDE vs FLOMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Category C
Category C
Alpha-1 Blocker
Alpha-1 Blocker